About this trial
Investigators combined the clinical and radiomics characteristics of resectable non-small cell lung cancer patients to construct an accurate model for preoperative prediction of mediastinal lymph node status. For the patients in the experimental group, lymph nodes will be dissected based on the predicted lymph node status by the model, while in the control group, the lymph nodes will be dissected according to the NCCN guidelines (2023). Investigators expect that performing lymph node dissection according to the predictive model can lead to better prognosis for patients.
Eligibility criteria
Qualifiers
Age range from 18 to 70 years old;
Chest CT shows a single pulmonary nodule, which may be adenocarcinoma or squamous cell carcinoma;
Chest CT shows multiple pulmonary nodules, but preoperative evaluation suggests that pulmonary nodules other than the main lesion are benign;
Preoperative auxiliary examination evaluates the patient as clinically resectable lung adenocarcinoma or squamous cell carcinoma in stages I, II, or IIIA (UICC-TNM 9th edition);
Disqualifiers
Chest CT suggests multiple primary lung cancer or metastatic cancer;
Previous history of thoracic surgery;
Previous history of malignant tumors;
History of neoadjuvant therapy;
Trial design
Treatments tested in this trial
- Lymph node dissection based on the guidelines
- Lymph node dissection based on the model